心脉医疗最新一期业绩显示，截至2025一季报，公司营业总收入3.32亿元、同比减少7.23%，归属净利 润1.30亿元，同比减少29.66%，扣非净利润1.22亿元，同比减少31.27%，流动比率6.284、速动比率 5.773、资产负债率13.00%。 天眼查商业履历信息显示，上海微创心脉医疗科技(集团)股份有限公司，成立于2012年，位于上海市， 是一家以从事研究和试验发展为主的企业。企业注册资本12326.2117万人民币，实缴资本5397.8147万人 民币。公司法定代表人为朱清。 金融界消息 截至2025年8月5日收盘，心脉医疗（688016）报收于111.89元，下跌1.37%，换手率 1.82%，成交量2.24万手，成交金额2.52亿元。 资金流向方面，今日主力资金净流出2609.57万元，占比成交额10.38%。其中，超大单净流出1320.54万 元、占成交额5.25%，大单净流出1289.02万元、占成交额5.13%，中单净流出流入1229.43万元、占成交 额4.89%，小单净流入1380.14万元、占成交额5.49%。 通过天眼查大数据分析，上海微创心脉医疗科技(集团)股份有限公司共对外 ...

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral vascular applications [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] Financial Performance - For Q1 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23% [2] - The net profit for the same period was 130 million yuan, down 29.66% year-on-year, with a gross profit margin of 69.61% [2] Market Position - As of August 5, the company's stock closed at 111.89 yuan, down 1.37%, with a rolling PE ratio of 30.82 times [1] - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing the company at 61st in industry rankings [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,176, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has experienced a stock price increase of 3.41% as of August 4, 2025, closing at 113.44 yuan, with a trading volume of 29,500 hands and a transaction amount of 328 million yuan [1] - The company reported a total operating revenue of 332 million yuan for Q1 2025, representing a year-on-year decrease of 7.23%, and a net profit attributable to shareholders of 130 million yuan, down 29.66% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 6.284 and a quick ratio of 5.773, while the debt-to-asset ratio stands at 13.00% [1] Group 2 - Xinmai Medical has made investments in 5 external companies and participated in 353 bidding projects, indicating active engagement in business development [2] - The company holds 41 trademark registrations and 202 patent filings, showcasing its focus on intellectual property [2] - Additionally, Xinmai Medical possesses 162 administrative licenses, reflecting its compliance and operational capabilities [2]

Core Viewpoint - The company, Xinmai Medical, has shown a slight increase in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential investment opportunities despite recent declines in revenue and profit [1][2]. Company Overview - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including aortic stent graft systems and balloon catheters [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, Xinmai Medical reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% from the previous year, with a gross margin of 69.61% [2]. Market Position - As of the latest data, Xinmai Medical's PE ratio stands at 31.25, while the industry average is 54.32, indicating that the company is undervalued relative to its peers [3]. - The total market capitalization of Xinmai Medical is approximately 13.983 billion yuan [1][3].

证券日报网讯8月4日晚间，心脉医疗发布公告称，2025年7月份，公司通过集中竞价交易方式已累计回 购公司A股股份137，330股，占公司总股本的比例为0.11%。 ...

Group 1 - As of August 4, 2025, the stock price of Xinmai Medical is 113.44 yuan, an increase of 3.74 yuan or 3.41% from the previous trading day [1] - On the same day, the trading volume was 29,521 hands, with a transaction amount of 328 million yuan [1] - Xinmai Medical primarily engages in the research, development, production, and sales of interventional medical devices for aorta and peripheral blood vessels [1] Group 2 - In Q1 2025, the company achieved operating revenue of 332 million yuan and a net profit of 130 million yuan [1] - As of July 31, 2025, Xinmai Medical has repurchased a total of 1.09 million shares, accounting for 0.89% of the total share capital, with a repurchase amount of 113 million yuan [1] - The repurchase price range was between 84.26 yuan/share and 119.82 yuan/share [1] Group 3 - On August 4, 2025, the net inflow of main funds was 29.44 million yuan, while the net outflow over the past five days was 24.67 million yuan [1]

重要内容提示： | 回购方案首次披露日（第二期） | 2024/10/30 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限（第二期） | 2024 年 10 月 10 | 28 | 日~2025 | 年 | 月 | 27 | 日 | | 预计回购金额（第二期） | 10,000万元~20,000万元 □减少注册资本 | | | | | | | | 回购用途 | √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数（第二期） | 1,091,171股 | | | | | | | | 累计已回购股数占总股本比例 | 0.89% | | | | | | | | （第二期） | | | | | | | | | 累计已回购金额（第二期） | 113,259,321.90元 | | | | | | | | 实际回购价格区间（第二期） | 84.26元/股~119.82元/股 | ...

Core Viewpoint - The company, Xinmai Medical (688016.SH), has announced its share repurchase program, indicating a commitment to enhancing shareholder value through stock buybacks [1] Summary by Categories Share Repurchase Details - As of July 31, 2025, the company has repurchased a total of 1.0912 million shares through the Shanghai Stock Exchange's centralized bidding system in the second phase of its buyback program [1] - The highest price paid for the repurchased shares was 119.82 RMB per share, while the lowest price was 84.26 RMB per share [1] - The total amount spent on the share repurchase reached 113 million RMB, excluding transaction fees such as stamp duty and commissions [1]

8月1日，沪深两融数据显示，心脉医疗获融资买入额0.31亿元，居两市第545位，当日融资偿还额0.29亿 元，净买入223.38万元。 最近三个交易日，30日-1日，心脉医疗分别获融资买入0.61亿元、0.59亿元、0.31亿元。 融券方面，当日融券卖出0.06万股，净卖出0.06万股。 来源：金融界 ...

Core Viewpoint - The company, Xinmai Medical, is experiencing a decline in stock price and financial performance, with a current PE ratio significantly lower than the industry average, indicating potential undervaluation in the context of the medical device sector [1][2]. Company Overview - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including thoracic and abdominal aortic stent graft systems, intraoperative stents, and balloon catheters [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 companies in the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, Xinmai Medical reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% from the previous year, with a gross margin of 69.61% [2]. - The current stock price is 111.61 yuan, with a PE ratio of 30.75, compared to the industry average of 55.15 and a median of 37.48 [1][3]. Shareholder Information - As of March 31, 2025, Xinmai Medical has 18,176 shareholders, an increase of 523 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1].